Muvalaplin
Based on 1 Customer Validation
Muvalaplin (LY3473329) is an orally active, selective small molecule inhibitor of lipoprotein (a) (Lp (a)) that disrupts the initial non-covalent interaction between apo(a) and apoB100, preventing the disulphide bond and Lp(a) formation. Muvalaplin reduces the levels of Lp (a) in transgenic mice and in cynomolgus monkeys.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.96%
- CAS. Nr.: 2565656-70-2
- Formel: C42H54N4O6
- Molecular Weight:710.90
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Lipoprotein(a) (Lp(a))[1]
Muvalaplin (1-100 mg/kg, p.o., daily for 15 days) reduces the levels of Lp (a) levels in cynomolgus monkeys[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Lp (a) transgenic mouse model[3]
-
Dosage:1-30 mg/kg
-
Administration:p.o., daily for 5 days
-
Result:Reduced the levels of Lp(a) with an absolute ED50 of 3 mg/kg.
-
Animal Model:Cynomolgus monkeys[3]
-
Dosage:1-100 mg/kg
-
Administration:p.o., daily for 15 days
-
Result:Reduced median Lp(a) levels in a dose-dependent manner by up to 71%.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 2565656-70-2
-
Appearance Solid
-
Molecular Weight 710.90
-
Formel C42H54N4O6
-
Color White to light yellow
-
SMILES
OC([C@H]([C@H]1CCNC1)CC2=CC(CN(CC3=CC(C[C@@H]([C@H]4CCNC4)C(O)=O)=CC=C3)CC5=CC(C[C@@H]([C@H]6CCNC6)C(O)=O)=CC=C5)=CC=C2)=O
-
Synonyms
LY3473329
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : 22.22 mg/mL (31.26 mM; ultrasonic and adjust pH to 7 with 1 M HCl; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Bhatia HS, et al. Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies. J Clin Med. 2022 Oct 13;11(20):6040. [Content Brief]
[2]. Nicholls SJ, et al. Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial. JAMA. 2023 Sep 19;330(11):1042-1053. [Content Brief]
[3]. Diaz N, et al. Discovery of potent small-molecule inhibitors of lipoprotein(a) formation. Nature. 2024 May;629(8013):945-950. [Content Brief]
[4]. Hooper AJ, et al. Potential of muvalaplin as a lipoprotein(a) inhibitor. Expert Opin Investig Drugs. 2024 Jan;33(1):5-7. [Content Brief]
[5]. Norata GD, et al. Oral strategies to target proprotein convertase subtilisin/kexin type 9 and lipoprotein(a): the new frontier of lipid lowering. Eur Heart J. 2023 Dec 21;44(48):5018-5020. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.4067 mL | 7.0333 mL | 14.0667 mL | 35.1667 mL |
| 5 mM | 0.2813 mL | 1.4067 mL | 2.8133 mL | 7.0333 mL | |
| 10 mM | 0.1407 mL | 0.7033 mL | 1.4067 mL | 3.5167 mL | |
| 15 mM | 0.0938 mL | 0.4689 mL | 0.9378 mL | 2.3444 mL | |
| 20 mM | 0.0703 mL | 0.3517 mL | 0.7033 mL | 1.7583 mL | |
| 25 mM | 0.0563 mL | 0.2813 mL | 0.5627 mL | 1.4067 mL | |
| 30 mM | 0.0469 mL | 0.2344 mL | 0.4689 mL | 1.1722 mL |
Muvalaplin Related Classifications
HY-152857 Related Classifications
Powered by Bioz